Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538266 | 1.00 | NPC1 (0.40) | NPC1RAB9AGAALMNAKCNK3 | |
| SCHEMBL3539428 | 0.87 | NPC1 (0.38) | NPC1RAB9AGAALMNAKCNK3 | |
| SCHEMBL3539429 | 0.87 | NPC1 (0.38) | NPC1RAB9AGAALMNAKCNK3 | |
| SCHEMBL3543076 | 0.84 | SLC6A9 (0.41) | NPC1RAB9AGAALMNA | |
| SCHEMBL3543072 | 0.84 | SLC6A9 (0.41) | NPC1RAB9AGAALMNA | |
| SCHEMBL5918378 | 0.74 | SLC6A9 (0.40) | NPC1RAB9AGAALMNAKCNK3 | |
| SCHEMBL3542194 | 0.73 | SLC6A9 (0.39) | NPC1RAB9AGAALMNA | |
| SCHEMBL3543389 | 0.73 | NPC1 (0.38) | NPC1RAB9AGAALMNAKCNK3 | |
| SCHEMBL3542190 | 0.73 | SLC6A9 (0.39) | NPC1RAB9AGAALMNA | |
| SCHEMBL3543390 | 0.73 | NPC1 (0.38) | NPC1RAB9AGAALMNAKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893566-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-7851638-B2 | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME LIMITED (GB) | 2010-12-14 | — | — | US | disclosed |
| US-20100029726-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-7626056-B2 | 2,4-Dichloro-N-(4-cyclopropylmethanesulfonyl-1-cyclopropylmethylcyclohexyl-methyl) benzamide; glutamatergic neurotransmission dysfunction and diseases; dementia; antidepressants; learning enhancement; cognition activators; attention deficit disorders; autism; eating disorders; anxiolytic agents | MERCK SHARP & DOHME LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | GLRA1, GNMT, MGAT1 | NPC1 390/4885RAB9A 3150/4885GAA 761/4885 |
| US-20100029726-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | GLRA1, GNMT, MGAT1 | NPC1 390/4885RAB9A 3150/4885GAA 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.